RE:RE:RE:RE:How Is Dart Playing This BetHi GV: I did a little thinking about one of your points in your recent posts and want to repsectfully amend my answer a bit. Here's the point: =====================================================================
4) Moreover, he’d have to continue investing in that losing concern (continued operations) in an event to garner enough positive data from the failed study to get some buyer interested in buying it. I think the end sale price would be pretty low - and compared to Dart’s investments over the years, he’d be lucky to get his money back...
GV: He does not need to keep investing . The RVX patent will simply be his property and he can do with it as he pleases. All emplyees and the Bof D will simply be let go. Don't forget he has his own Pharma so he may continue with the RVX patents in that way . ========================================================
SF99: What I wanted to add about this is this: I do think he would have to keep investing. The asset (RVX patents) would be near worthless after that failed future trial. To resusitate the patient and increase the value of the assets, they would need to do a lengthy post-hoc analysis just like this did this past year. That would require hanging on to key staff during this process, which could take up to a year. Plus, those employees would also be needed to help sell any potential purchasers on the value of the patents themselves.
Thus, I think that in the event of a failed trial, Dart's investments in the company would have to continue in order to salvage some value at that time.
Just something to consider in the overall analysis..... IMHO of course.